Stockreport

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, t [Read more]